Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | TNF | P01375 | 2/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18932868 | 0.90 | NOD1 (0.45) | NOD1TNFNOD2PKMMEN1 | |
| SCHEMBL6660012 | 0.89 | THRA (0.48) | NOD1TNFNOD2PKMMEN1 | |
| SCHEMBL7056850 | 0.86 | THRA (0.43) | TNFPKMMEN1KMT2ANPC1 | |
| SCHEMBL6657849 | 0.85 | THRA (0.47) | THRATHRB | |
| SCHEMBL6656734 | 0.84 | GRIN2D (0.50) | NOD1TNFNOD2PKMMEN1 | |
| SCHEMBL18932871 | 0.84 | EPHX1 (0.39) | THRATHRB | |
| SCHEMBL6662531 | 0.82 | THRB (0.42) | THRATHRBALDH1A1L3MBTL1 | |
| SCHEMBL6662829 | 0.80 | THRA (0.43) | THRATHRBALDH1A1L3MBTL1 | |
| SCHEMBL6658762 | 0.77 | THRB (0.42) | KMT2AKDM4ETHRATHRB | |
| SCHEMBL18932864 | 0.77 | ABL1 (0.43) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | claimed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | claimed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | claimed |
| EP-1157001-B1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | disclosed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | disclosed |
| US-6326398-B1 | Oxamic acids and derivatives as thyroid receptor ligands | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
| EP-1157001-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051971-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, TSHR | NOD1 1677/4885TNF 1793/4885NOD2 3381/4885 |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, OXGR1 | NOD1 1661/4885TNF 2077/4885NOD2 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.